Back to Top
Vilastobart Biosimilar - Research Grade
$710.00 - $6,900.00
Vilastobart Biosimilar - Research Grade
Endotoxin
≤ 1.0 EU/mg as determined by the LAL method
Purity
>90% by SDS-PAGE
Species Reactivity
Human
Target
CTLA4ï؟½
Concentration
5mg/ml
Isotype
IgG1 - kappa
Host
CHO Cells
Sequence
https://www.imgt.org/mAb-DB/
Buffer
ICH3002
Uniprot
P09793;P16410
Shipping Conditions
Blue ice
Background
CTLA-4 is a critical co-inhibitory checkpoint that limits T-cell priming and stands among the most investigated targets in immuno-oncology research. This recombinant human IgG1 antibody is an unconjugated, non-therapeutic analog of vilastobart directed against CTLA-4 and is supplied for research use only (RUO). It is purified to a low-endotoxin standard appropriate for in vivo studies and manufactured in scalable milligram-to-gram quantities to support heavy-usage and high-throughput laboratories. Investigators apply it as a checkpoint-blockade control and functional reagent across in vitro T-cell activation assays, ADCC studies, and preclinical tumor immunotherapy models.
Purification Method
This monoclonal antibody was purified using Protein A
Formulation
Sterile, preservative-free, solution in PBS. BSA and Azide free.
Storage
This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.
Applications
Functional Assays
Application Notes
This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.
Use
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Delivery Time
3-4 weeks
Write Your Own Review












